Effects of the phosphodiesterase-III inhibitor enoximone on skeletal muscle specimens from malignant hyperthermia susceptible patients

Journal of Clinical Anesthesia

Volumn 12, Issue 2, 2000, Pages 123-128

  Fiege, Marko ^a   Wappler, Frank ^a   Scholz, Jens ^a   Weisshorn, Ralf ^a   Von Richthofen, Verena ^a   Schulte Am Esch, Jochen ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cafffeine; Enoximone; Halothane; Malignant hyperthermia; Phosphodiesterase

Indexed keywords

CAFFEINE; ENOXIMONE; HALOTHANE; PHOSPHODIESTERASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; MUSCLE CONTRACTION; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; SCHOOL CHILD; SKELETAL MUSCLE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADOLESCENT; ADULT; AGED; BIOPSY; CHILD; CULTURE TECHNIQUES; CYCLIC AMP; DISEASE SUSCEPTIBILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXIMONE; FEMALE; HUMANS; MALE; MALIGNANT HYPERTHERMIA; MIDDLE AGED; MUSCLE CONTRACTION; MUSCLE, SKELETAL; PHOSPHODIESTERASE INHIBITORS; PROSPECTIVE STUDIES;

EID: 0034014815     PISSN: 09528180     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-8180(00)00124-0     Document Type: Article

References (26)

1. 2+ regulation defects . Physiol Rev. 76:1996;537-592.
2. 2+ release channels in malignant hyperthermic skeletal muscle. Biophys J. 59:1991;1085-1090.
3. Fletcher J.E., Tripolitis L., Erwin K., et al. Fatty acids modulate calcium-induced calcium release from skeletal muscle heavy sarcoplasmic reticulum fractions implications for malignant hyperthermia . Biochem Cell Biol. 68:1990;1195-1201.
4. Foster P.S., Gesini E., Claudianos C., Hopkinson K.C., Denborough M.A. Inositol 1,4,5-trisphosphate phosphatase deficiency and malignant hyperpyrexia in swine. Lancet. 2:1989;124-127.
5. 2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients. Anesthesiology. 84:1996;1280-1287.
6. Willner J.H., Cerri C.G., Wood D.S. High skeletal muscle adenylate cyclase in malignant hyperthermia. J Clin Invest. 68:1981;1119-1124.
7. Ellis F.R., Halsall P.J., Allam P., Hay E. A biochemical abnormality found in muscle from unstressed malignant-hyperpyrexia-susceptible humans. Biochem Soc Trans. 12:1984;357-358.
8. 2-adrenoceptors in skeletal and cardiac muscle . Acta Anaesthesiol Scand. 37:1993;575-583.
9. Stanec A., Stefano G. Cyclic AMP in normal and malignant hyperpyrexia susceptible individuals following exercise. Br J Anaesth. 56:1984;1243-1246.
10. Schmitz W., von der Leyen H., Meyer W., Neumann J., Scholz H. Phosphodiesterase inhibition and positive inotropic effects. J Cardiovasc Pharmacol. 14:1989;S11-S14.
11. Scholz H. PDE inhibition as a therapeutic principal. Z Kardiol. 83:1994;1-5.
12. Hartung E., Rauch A., Rübsam B., Preis I., Sold M., Engelhardt W. Cyclic AMP and phosphodiesterase inhibition in skeletal muscle a potent trigger or a cofactor for malignant hyperthermia? Minerva Anestesiol. 60:1994;65-71.
13. Fiege M., Wappler F., Scholz J., von Richthofen V., Brinken B., Schulte am Esch J. Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase-III-inhibitor enoximone. Anästhesiol Intensivmed Notfallmed Schmerzther. 33:1998;557-563.
14. Ording H., Brancadoro V., Cozzolino S., et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group . Acta Anaesthesiol Scand. 41:1997;955-966.
15. Allen G.C., Larach M.G., Kunselman A.R. The sensitivity and specificity of the caffeine-halothane contracture test a report from the North American Malignant Hyperthermia Registry . Anesthesiology. 88:1998;579-588.
16. Isaacs H., Badenhorst M. False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology. 79:1993;5-9.
17. Wedel D.J., Nelson T.E. Malignant hyperthermia - diagnostic dilemma false-negative contracture responses with halothane and caffeine alone . Anesth Analg. 78:1994;787-792.
18. Hopkins P.M., Ellis F.R., Halsall P.J. Ryanodine contracture a potentially specific in vitro diagnostic test for malignant hyperthermia . Br J Anaesth. 66:1991;611-613.
19. Hopkins P.M., Hartung E., Wappler F. Multicentre evaluation of ryanodine contracture testing in malignant hyperthermia. Br J Anaesth. 80:1998;389-394.
20. 2+-channel. Anesthesiology. 84:1996;1380-1385.
21. Nicholson C.D., Challiss R.A., Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci. 12:1991;19-27.
22. Thompson W.J. Cyclic nucleotide phosphodiesterases pharmacology, biochemistry and function . Pharmacol Ther. 51:1991;13-33.
23. Willner J.H., Cerri C.J., Wood D.S. Malignant hyperthermia abnormal cyclic AMP metabolism in skeletal muscle . Neurology. 29:1979;557.
24. Jähnchen E., Trenk D. Pharmacology and pharmacokinetics of enoximone. Z Kardiol. 80:1991;21-26.
25. Trenk D., Jähnchen E. Clinico-pharmacologic aspects of enoximone therapy. Z Kardiol. 83:1994;7-14.
26. Dage R.C., Okerholm R.A. Pharmacology and pharmacokinetics of enoximone. Cardiology. 77:1990;2-13.